CN104470501A - 两性螯合剂用于预防接触性过敏的用途 - Google Patents
两性螯合剂用于预防接触性过敏的用途 Download PDFInfo
- Publication number
- CN104470501A CN104470501A CN201380037698.8A CN201380037698A CN104470501A CN 104470501 A CN104470501 A CN 104470501A CN 201380037698 A CN201380037698 A CN 201380037698A CN 104470501 A CN104470501 A CN 104470501A
- Authority
- CN
- China
- Prior art keywords
- sexes
- chelating agen
- equipment
- ethylenediaminetetraacetic acid
- integer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010020751 Hypersensitivity Diseases 0.000 title claims abstract description 13
- 230000007815 allergy Effects 0.000 title claims abstract description 12
- 239000002738 chelating agent Substances 0.000 title abstract 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims abstract description 16
- 229910052782 aluminium Inorganic materials 0.000 claims abstract description 11
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims abstract description 10
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims abstract description 8
- 239000000203 mixture Substances 0.000 claims description 54
- -1 antiseptic Substances 0.000 claims description 21
- 206010070834 Sensitisation Diseases 0.000 claims description 18
- 230000008313 sensitization Effects 0.000 claims description 18
- 239000003349 gelling agent Substances 0.000 claims description 13
- 238000009472 formulation Methods 0.000 claims description 11
- 210000004877 mucosa Anatomy 0.000 claims description 11
- 208000026935 allergic disease Diseases 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 9
- 239000000314 lubricant Substances 0.000 claims description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 8
- 208000007811 Latex Hypersensitivity Diseases 0.000 claims description 8
- 150000002500 ions Chemical class 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 239000002537 cosmetic Substances 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- 229920001817 Agar Polymers 0.000 claims description 4
- 241001597008 Nomeidae Species 0.000 claims description 4
- 235000010489 acacia gum Nutrition 0.000 claims description 4
- 239000008272 agar Substances 0.000 claims description 4
- 235000010419 agar Nutrition 0.000 claims description 4
- 230000001166 anti-perspirative effect Effects 0.000 claims description 4
- 239000003213 antiperspirant Substances 0.000 claims description 4
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 239000003974 emollient agent Substances 0.000 claims description 4
- 238000003786 synthesis reaction Methods 0.000 claims description 4
- 239000002562 thickening agent Substances 0.000 claims description 4
- 239000000080 wetting agent Substances 0.000 claims description 4
- 229920001285 xanthan gum Polymers 0.000 claims description 4
- 235000010493 xanthan gum Nutrition 0.000 claims description 4
- 239000000230 xanthan gum Substances 0.000 claims description 4
- 229940082509 xanthan gum Drugs 0.000 claims description 4
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 claims description 3
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 3
- 206010010741 Conjunctivitis Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 239000004471 Glycine Substances 0.000 claims description 3
- 229920002305 Schizophyllan Polymers 0.000 claims description 3
- 239000000654 additive Substances 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 239000000989 food dye Substances 0.000 claims description 3
- 235000013355 food flavoring agent Nutrition 0.000 claims description 3
- 239000003002 pH adjusting agent Substances 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 235000013599 spices Nutrition 0.000 claims description 3
- 229940099259 vaseline Drugs 0.000 claims description 3
- 239000001993 wax Substances 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 239000004475 Arginine Substances 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 2
- 240000008886 Ceratonia siliqua Species 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 229920002148 Gellan gum Polymers 0.000 claims description 2
- 229920001503 Glucan Polymers 0.000 claims description 2
- 229920002907 Guar gum Polymers 0.000 claims description 2
- 229920000084 Gum arabic Polymers 0.000 claims description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 208000005279 Status Asthmaticus Diseases 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 206010046742 Urticaria contact Diseases 0.000 claims description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 2
- 239000000205 acacia gum Substances 0.000 claims description 2
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 2
- 230000000996 additive effect Effects 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 229920000615 alginic acid Polymers 0.000 claims description 2
- 235000010443 alginic acid Nutrition 0.000 claims description 2
- HZVVJJIYJKGMFL-UHFFFAOYSA-N almasilate Chemical compound O.[Mg+2].[Al+3].[Al+3].O[Si](O)=O.O[Si](O)=O HZVVJJIYJKGMFL-UHFFFAOYSA-N 0.000 claims description 2
- 229940024606 amino acid Drugs 0.000 claims description 2
- 235000001014 amino acid Nutrition 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 238000005266 casting Methods 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 229920006037 cross link polymer Polymers 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000010492 gellan gum Nutrition 0.000 claims description 2
- 239000000216 gellan gum Substances 0.000 claims description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 2
- 235000010417 guar gum Nutrition 0.000 claims description 2
- 239000000665 guar gum Substances 0.000 claims description 2
- 229960002154 guar gum Drugs 0.000 claims description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229930182817 methionine Natural products 0.000 claims description 2
- 239000003921 oil Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 229960000502 poloxamer Drugs 0.000 claims description 2
- 229920002401 polyacrylamide Polymers 0.000 claims description 2
- 229920001296 polysiloxane Polymers 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 230000001235 sensitizing effect Effects 0.000 claims description 2
- 239000000377 silicon dioxide Substances 0.000 claims description 2
- 235000012239 silicon dioxide Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- 239000004474 valine Substances 0.000 claims description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000004411 aluminium Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 21
- 229920001971 elastomer Polymers 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 210000002615 epidermis Anatomy 0.000 description 10
- 244000043261 Hevea brasiliensis Species 0.000 description 9
- 239000004816 latex Substances 0.000 description 9
- 229920000126 latex Polymers 0.000 description 9
- 239000000839 emulsion Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 101800002189 Hevein Proteins 0.000 description 6
- WKMZPSWMEXVKKG-XITFREQTSA-N hevein Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CS)C(=O)NCC(=O)OC(=O)CC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CNC2=CC=CC=C12 WKMZPSWMEXVKKG-XITFREQTSA-N 0.000 description 6
- 229920003052 natural elastomer Polymers 0.000 description 6
- 229920001194 natural rubber Polymers 0.000 description 6
- 231100000489 sensitizer Toxicity 0.000 description 6
- 239000010410 layer Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000004888 barrier function Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 229940081733 cetearyl alcohol Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003822 epoxy resin Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 3
- 229920000647 polyepoxide Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- KUAZQDVKQLNFPE-UHFFFAOYSA-N thiram Chemical compound CN(C)C(=S)SSC(=S)N(C)C KUAZQDVKQLNFPE-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JLHMJWHSBYZWJJ-UHFFFAOYSA-N 1,2-thiazole 1-oxide Chemical compound O=S1C=CC=N1 JLHMJWHSBYZWJJ-UHFFFAOYSA-N 0.000 description 2
- YXIWHUQXZSMYRE-UHFFFAOYSA-N 1,3-benzothiazole-2-thiol Chemical compound C1=CC=C2SC(S)=NC2=C1 YXIWHUQXZSMYRE-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 102000006395 Globulins Human genes 0.000 description 2
- 108010044091 Globulins Proteins 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000011195 Profilin Human genes 0.000 description 2
- 108050001408 Profilin Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 206010039251 Rubber sensitivity Diseases 0.000 description 2
- 101710123661 Venom allergen 5 Proteins 0.000 description 2
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 229910052793 cadmium Inorganic materials 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 201000005391 latex allergy Diseases 0.000 description 2
- 229910052745 lead Inorganic materials 0.000 description 2
- 108010053156 lipid transfer protein Proteins 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 210000000438 stratum basale Anatomy 0.000 description 2
- 229910052712 strontium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052714 tellurium Inorganic materials 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229960002447 thiram Drugs 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 description 1
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N 5-oxoproline Chemical compound OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 229930185605 Bisphenol Natural products 0.000 description 1
- LVDKZNITIUWNER-UHFFFAOYSA-N Bronopol Chemical compound OCC(Br)(CO)[N+]([O-])=O LVDKZNITIUWNER-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 108010022172 Chitinases Proteins 0.000 description 1
- 102000012286 Chitinases Human genes 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000004593 Epoxy Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 244000286663 Ficus elastica Species 0.000 description 1
- 101000992159 Homo sapiens Oncomodulin-1 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108050004114 Monellin Proteins 0.000 description 1
- 101000952180 Morus alba Mulatexin Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 102100031945 Oncomodulin-1 Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 229920002367 Polyisobutene Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Natural products OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000005937 Tropomyosin Human genes 0.000 description 1
- 108010030743 Tropomyosin Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 101710196023 Vicilin Proteins 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- ILXDAXZQNSOSAE-UHFFFAOYSA-N [AlH3].[Cl] Chemical compound [AlH3].[Cl] ILXDAXZQNSOSAE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000001994 activation Methods 0.000 description 1
- 208000024716 acute asthma Diseases 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
- 229940009840 aluminum chlorhydrate Drugs 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- BTFJIXJJCSYFAL-UHFFFAOYSA-N arachidyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- JSCZQQBVWYGODV-UHFFFAOYSA-N bis(octadecoxycarbonyl) carbonate Chemical class CCCCCCCCCCCCCCCCCCOC(=O)OC(=O)OC(=O)OCCCCCCCCCCCCCCCCCC JSCZQQBVWYGODV-UHFFFAOYSA-N 0.000 description 1
- IISBACLAFKSPIT-UHFFFAOYSA-N bisphenol A Chemical compound C=1C=C(O)C=CC=1C(C)(C)C1=CC=C(O)C=C1 IISBACLAFKSPIT-UHFFFAOYSA-N 0.000 description 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- DKVNPHBNOWQYFE-UHFFFAOYSA-N carbamodithioic acid Chemical compound NC(S)=S DKVNPHBNOWQYFE-UHFFFAOYSA-N 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 229940073669 ceteareth 20 Drugs 0.000 description 1
- 229940074979 cetyl palmitate Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000012990 dithiocarbamate Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000007046 ethoxylation reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 150000002194 fatty esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229940098330 gamma linoleic acid Drugs 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940119170 jojoba wax Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- CBFCDTFDPHXCNY-UHFFFAOYSA-N octyldodecane Natural products CCCCCCCCCCCCCCCCCCCC CBFCDTFDPHXCNY-UHFFFAOYSA-N 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000000006 pectoral fin Anatomy 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920002851 polycationic polymer Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 229920001195 polyisoprene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000003001 serine protease inhibitor Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/51—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Detergent Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Preventing Corrosion Or Incrustation Of Metals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明涉及至少一种两性螯合剂用于预防接触性过敏的用途，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，和c’是具有与c相同的绝对值的相对数。本发明还涉及其一部分包含所述两性螯合剂的设备。
Description
发明领域
本发明涉及用于预防接触性过敏的产品的领域。
发明背景
接触性过敏，尤其是接触由橡胶制成的物体或设备引起的过敏，在过去几年中极大增加。尽管它们通常是温和的，但某些情况的症状可能具有严重后果。实际上，过敏可以为两种类型：
-急性荨麻疹、鼻炎、结膜炎、哮喘和过敏风险(休克和/或窒息状态)；
-迟发性过敏性接触性皮炎(湿疹)。
接触性过敏通过反复接触致敏物质产生。
对橡胶，尤其是乳胶，更尤其是天然乳胶过敏，影响1％-5％的人群。它尤其影响暴露于反复接触橡胶的个人，例如在医疗部门工作的个人。因此，5％-22％的医疗人员、护士、医生、外科医生、物理治疗师、足病医生发生橡胶过敏。经历了多次操作的患者也容易发生乳胶过敏，就像在实验室或美发沙龙工作使用橡胶手套的个人，使用涉及避孕套的避孕方法的个人，和在橡胶工厂工作的个人。
橡胶过敏代表引起麻醉期间过敏性休克的第二常见原因。自从1980年代末，天然橡胶(LN)过敏已经被公认为一个公共健康问题。
天然橡胶或乳胶是由一层水溶性蛋白覆盖的聚异戊二烯球形液滴的水性乳液。它可以是合成或天然来源。在天然形式中，它来自于橡胶树(Hevea brasiliensis)的汁液。它在日常生活的物体中广泛存在。由乳胶制成或包含乳胶因此能够引起过敏反应的物体的实例可提及家用手套、轮胎、气球、奶嘴、呼吸管、脚蹼、泳镜、浴帽、粘合剂、网球拍握把、避孕套、医用材料：弹性绷带、带橡胶密封圈的注射器、导管、undersheet、灌注管、牙科护理口罩和检查手套或手术手套等。
预防接触性过敏的最好方法是避免使用和/或接触含有致敏物质的物体。因此，为了预防橡胶过敏，建议不要使用由橡胶制成的物体。
替代产品的存在，尤其是由聚氨酯、聚乙烯、腈等制成的产品，使替代由橡胶制成的物体或设备变为可能，但是它们被证明贵得多，且对于指套、手套和避孕套，它们影响接触敏感性。因此确实需要一种可以预防接触性过敏和尤其是对橡胶过敏的产品。
令人惊讶且出乎意料地，本发明人发现一种特定的两性螯合剂可以预防接触性过敏。
发明简述
总体上，本发明涉及至少一种两性螯合剂用于预防接触性过敏的用途，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，和c’是具有与c相同的绝对值的相对数。
根据另一个方面，本发明涉及包含由致敏材料，尤其是由乳胶制成的部分、意欲与皮肤或黏膜接触的设备，该设备由包含至少一种上述两性螯合剂的层覆盖。
根据另一个主题，本发明涉及包含至少一种上述两性螯合剂和至少一种赋形剂的组合物用于预防接触性过敏的用途。
发明详述
本发明涉及至少一种两性螯合剂用于预防接触性过敏，尤其是对橡胶过敏的用途，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，和c’是具有与c相同的绝对值的相对数。
在本发明中，术语“接触性过敏”是指皮肤和/或黏膜反复接触致敏物质而引起的所有过敏。容易与皮肤和/或黏膜接触的物体或设备中存在的引起接触性过敏的过敏原的实例可提及乳胶蛋白、重金属例如Al、As、Cd、Cr、Hg、Ni、Pb、Sr和Te、二硫化四甲基秋兰姆、2-巯基苯并噻唑、氨基甲酸苄酯、双酚、丙烯酸乙酯、环氧树脂506环氧树脂、甲醛、蛋白类过敏原(例如抑制蛋白、原肌球蛋白、LTP(脂质转移蛋白)、PR-10bet v1样蛋白、Polcacin、β小白蛋白、2s白蛋白、β膨胀素、多聚半乳糖醛酸酶、Ag5(抗原5)、白蛋白、酪蛋白、载脂蛋白、第5组草过敏原、11s球蛋白、7s豌豆球蛋白样球蛋白、第4组草过敏原、木瓜蛋白酶样半胱氨酸蛋白酶、磷脂酶A1、丝氨酸蛋白酶抑制剂、透明质酸酶、1类几丁质酶、类甜蛋白等)及其混合物。
本发明尤其适用于预防对橡胶的过敏，尤其是对天然橡胶的过敏。在本发明中，术语“对橡胶过敏”意欲指由衍生自橡胶树的天然橡胶中存在的蛋白质引起的过敏，也指在橡胶中存在的其他致敏物质引起的过敏。此类致敏蛋白的实例可提及橡胶蛋白、原橡胶蛋白、抑制蛋白、橡胶延长因子、内切-1,3-β-葡萄糖苷酶等。橡胶中存在的非蛋白质致敏物质的其他实例是硫化剂(秋兰姆、二硫代氨基甲酸酯、苯并噻唑、胍和硫脲)、抗氧化剂或抗臭氧剂(衍生自PPD-对苯二胺-和喹啉)、酚(对苯二酚)、亚磷酸盐等、或其他添加剂，例如葡萄糖酸氯己定、双十烷基二甲基氯化铵盐、异噻唑啉酮、甲醛、各种金属等。
这种接触性过敏本身通过接触性皮炎、接触性荨麻疹、湿疹、鼻炎、结膜炎、哮喘和过敏性休克来表现。
在本发明上下文中，术语“接触性过敏”或“对橡胶过敏”不区分过敏和其表现。
根据本发明所使用的通式[Al(Y)Bn]c’Dc的两性螯合剂优选通过铝离子Al3+、配体Y和选自OH-、BO2 -或H+的稳定剂的准化学计量组合(virtually stoichiometric combination)形成。因此，其pH保持中性，其最小酸pK值在6-10范围内，其最大基础pK值在5-8范围内，且其最大基础pK低于最小酸pK。
根据一个具体的实施方案，所述基于铝和Y的络合物用弱碱例如选自甘氨酸、组氨酸、精氨酸、赖氨酸、苯丙氨酸、丙氨酸、异亮氨酸、亮氨酸、蛋氨酸、脯氨酸，缬氨酸、色氨酸、丝氨酸、谷氨酰胺、胱氨酸和它们的混合物的氨基酸来稳定。甘氨酸完全适合。
根据本发明，所述两性螯合剂的使用通过将其接触皮肤和/或黏膜来进行。
使用根据本发明的两性螯合剂的效力采用基于以下理论的形态学分析来测试：Langerhan细胞是在包含Birbeck颗粒的表皮中发现的树突状细胞。它们通常存在于淋巴结中和皮肤中的表皮棘层水平处。这些特异性摄取抗原的细胞在当皮肤接触过敏原时被激活。这提供敏化过程开始的第一个迹象。免疫标记方法，尤其是针对Langerhan细胞的CD1a表面受体的免疫标记方法，使得测量它们的数量以及观察它们从表皮到真皮的迁移变为可能。如果抗原被阻止，例如没有被表皮Langerhan细胞摄取，本发明的预防组合物是有效的。因此所述细胞不会迁移到真皮。因此，根据本发明所述的组合物的效力通过每厘米表皮非迁移Langerhan细胞数测量。将由本发明所述的组合物覆盖的皮肤区域接触致敏剂(尤其是天然橡胶的致敏蛋白，如橡胶蛋白)后没有观察到这些细胞数的明显迁移。
本发明也涉及包含由可能含有过敏原的材料制成的部分、意欲与皮肤或黏膜接触的设备，该设备由包含至少一种两性螯合剂的层覆盖，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，c’是具有与c相同的绝对值的相对数。
本发明尤其适用于由橡胶制成或包含由意欲与皮肤和/或黏膜接触的橡胶制成的部分的设备。
根据本发明所述的设备的实例是避孕套、手套、指套、绷带和止血敷料、医疗设备例如导管、管、排水设备、灌注装置、用于泌尿科的医疗设备、用于呼吸通道的医疗设备等。
根据一个具体的实施方案，意欲与皮肤和/或黏膜接触的设备的至少一部分由包含所述两性螯合剂的膜覆盖。
所述膜优选是润滑制剂。
在避孕套的情况下，其外表面和内表面都可以由包含所述两性螯合剂的润滑制剂覆盖以防止配偶对乳胶过敏。
本发明还涉及包含至少一种两性螯合剂和至少一种赋形剂的组合物用于预防接触性过敏，尤其是对橡胶的过敏的用途，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，c’是具有与c相同的绝对值的相对数。
组合物可以是水包油或油包水乳液的形式、或凝胶(尤其是亲水性凝胶或硅胶)的形式。
所述组合物中存在的赋形剂是药物或化妆品质量的赋形剂。
根据本发明所述的组合中可能存在的赋形剂的实例选自胶凝剂、表面活性剂、合成或天然的蜡或油、保湿剂和润肤剂、止汗剂、质地改进添加剂、例如调节剂和增稠剂、防腐剂、化妆品和食品染料、香料、调料、pH调节剂、和它们的混合物。
胶凝剂或增稠剂可以是亲水或可以是硅氧烷型。亲水性胶凝剂可以是合成胶凝剂、半合成胶凝剂、或植物、微生物、动物或矿物来源的天然胶凝剂。亲水性胶凝剂可以是，例如丙烯酸聚合物和共聚物、C10-C30烷基丙烯酸酯/丙烯酸酯交联聚合物、聚丙烯酰胺、泊洛沙姆、纤维素基衍生物(酯和醚)、二氧化硅、气相二氧化硅、硅酸盐例如镁-铝硅酸盐、甲壳素及其衍生物、明胶、黄原胶、葡聚糖、结冷胶、角叉菜胶、藻酸盐、琼脂、琼脂、果胶、金合欢树胶、刺梧桐胶、黄蓍胶、阿拉伯胶、瓜尔豆胶、角豆胶、淀粉及其衍生物、或硬葡聚糖。胶凝剂或增稠剂的浓度是组合物总重量的0.1-10重量％，优选0.1-5重量％，甚至更优选0.5-3重量％。
硅氧烷型胶凝剂是，例如聚硅氧烷。
表面活性剂可以是HLB为3-10的疏水表面活性剂或HLB为11-18的亲水表面活性剂。该表面活性剂选自乙氧基化脂肪醇、脂肪酸和脂肪酯(例如：鲸蜡硬脂醇聚醚-12、鲸蜡硬脂醇聚醚-20、鲸蜡硬脂醇聚醚-33、20-乙氧基化硬脂鲸蜡醇、聚甘油基-2聚羟基硬脂酸酯、油酸甘油酯、山梨糖醇酯、甘油酯、PEG-单/二月桂酸酯、PEG-单/二硬脂酸酯、异壬酸鲸蜡硬脂醇、硬脂酸甘油酯等)、羧酸酯、乙氧基羧酸盐(例如：硬脂酸钠/钾、烷基羧酸、烷基聚乙二醇醚羧酸、聚氧乙烯烷基酚醚羧酸、羧甲基化醇、乙氧基羧酸盐、醚羧酸盐等)及其混合物。当其存在时，表面活性剂的含量是组合物总重量的0.1-10重量％，优选0.5-5重量％，甚至更优选1-3重量％。
合成的或天然的蜡或油选自棕榈提取物、蜂蜡、乳木果油、甘油三酯、硬脂、脂肪酸酯(例如：鲸蜡硬脂醇、鲸蜡醇棕榈酸酯二辛酰醚(dicaprylyl ethers of cetyl palmitate)、碳酸二辛酰脂、壬酸鲸蜡硬脂、二硬脂酰-三碳酸盐二聚体等)、硅酮油、硬脂酸锌、聚异丁烯、辛基十二烷醇、辛癸木糖苷、脂肪醇、脂肪酸(例如：月桂酸、肉豆蔻酸、硬脂酸等)、植物油(例如：葵花油、荷荷巴油、椰子油、大豆油、杏仁油等)、凡士林、羊毛脂、和它们的混合物。
保湿剂和润肤剂可以选自尿囊素、多元醇(例如甘油、甘油聚合物、丙二醇、山梨醇等)、植物提取物(例如芦荟、洋甘菊、黄瓜、金盏花等的提取物)、透明质酸、吡咯烷酮羧酸、尿素、壳聚糖、生育酚、泛醇、丁二醇、磷脂、亚油酸、γ-亚油酸、α-没药醇和它们的混合物。
保湿剂和润肤剂的浓度是组合物总重量的0.1-20重量％，优选0.5-10重量％，甚至更优选1-5重量％。
止汗剂可以选自铝盐，优选半盐酸铝、铝和锆的盐、八氯甘氨酸铝锆络合物和它们的混合物。止汗剂的浓度是组合物总重量的0.1-50重量％，优选10-30重量％，甚至更优选15重量％。
调节剂可以选自根据INCI命名法表示的聚阳离子聚合物，例如聚季铵盐、季铵化胶、季铵化磷脂和它们的混合物。调节剂的浓度是组合物总重量的0.1-20重量％，优选0.5-10重量％，甚至更优选0.5-5重量％。
防腐剂可以选自：对羟基苯甲酸烷基酯、异噻唑啉酮、咪唑烷基脲、双咪唑烷基脲、溴硝基丙二醇、苯氧乙醇、山梨酸及其盐、苯甲酸及其盐、苯氧乙醇、苯甲醇和它们的混合物。浓度是化妆品中允许的浓度。
化妆品和食品染料、香料、调料、pH调节剂(例如柠檬酸、乳酸、磷酸、氢氧化钠、氢氧化钾、氨甲基丙醇，三乙醇胺等)、和它们的混合物的浓度是组合物总重量的0.1-50重量％，优选10-30重量％，甚至更优选15重量％。
尤其有利的，组合物是凝胶制剂，特别是润滑制剂。
所述润滑制剂是含有所述两性螯合剂的液体形式或固体形式的亲水性制剂、硅氧烷制剂或凡士林基润滑制剂。
所述组合物中存在的两性螯合剂的含量是组合物总重量的0.01％-5％，优选0.02％-4.4％，甚至更优选约2％。对于某些应用，当过敏原含量非常低，尤其是当使用脱蛋白乳胶时，非常少量，甚至低于0.01％，可能被证明是足够的。然而，在多数情况下，低于0.01％的含量不能获得足够的预防效果。高于5％没有观察到显著改善。
根据本发明，组合物通过局部应用，尤其是局部应用于皮肤来使用。它也可以通过应用于意欲与皮肤和/或黏膜接触的设备表面来使用。
不希望受限于理论，本发明人的观点是，根据本发明的组合物使得对过敏原产生物理和化学屏障变为可能。更具体的，在应用并干燥后，屏障层覆盖皮肤，因此在皮肤和外部环境间提供了物理屏障，至于两性螯合剂，它通过与该组合物接触的过敏原的螯合或化学反应提供了化学屏障。
通过该双重反应，阻止了过敏原与皮肤的接触。
为了使其有效，组合物必须完全覆盖容易与乳胶设备接触的皮肤和/或黏膜区域，通常是戴乳胶手套的手或戴避孕套的性器官。它必须应用于接触的整个表面。根据本发明所述的组合物的应用量的比例为约0.5-5mg/cm2、优选约1-3mg/cm2、更优选约2mg/cm2。
具体实施方式
以下实施例描述本发明的某些实施方案。然而，应理解，实施例仅为说明的目的存在，而不以任何方式限制本发明的范围。
在本实施例中，所用的两性螯合剂具有下式：[AlYBO2]2-Na+ 2。
实施例1-润滑组合物
制备包含以下组分的润滑组合物：
实施例2：凝胶
49.5ml水
0.5g黄原胶
0.2mg两性螯合剂。
该凝胶通过以下方法制备：将水倒入容器中。进行搅拌，同时加入黄原胶和两性螯合剂。将混合物静置10分钟。
进行混合以获得光滑的质地。
实施例3：外用乳液
制备包含以下产品的乳液。
该水包油乳液具有以下特征：
–温度20(+/-1)℃，主轴转速3/20rpm(0.94rad/min)下测得的Brookfield粘度为18000cP，
–pH6.45，
–室温下储存6个月后没有发生相分离。
实施例4：针对过敏原的效力测试
制备来自于一位49岁白种女性腹部整形的平均直径为10mm的皮肤外植体。在富含5％CO2的潮湿气氛下于37℃下在BEM(BIO-EC外植体培养基)培养基中维持这些外植体的活性。
针对以下过敏原测试实施例3组合物：
·重金属(Al、As、Cd、Cr、Hg、Ni、Pb、Sr、Te)-ECP多元素标准V参考0C467028Merck；
·二硫化四甲基秋兰姆-T2420；
·2-巯基苯并噻唑-M3301；
·氨基甲酸苄酯-B18200；
·双酚-13302；
·丙烯酸乙酯-W241806；
·环氧树脂506环氧树脂-A3183；
·橡胶蛋白-乳胶4335932；
·30％w/w甲醇-11699031。
在T0，以剂量3mg/cm2将上述实施例3组合物施用于皮肤外植体。使其干燥15分钟。然后将25μl选自上述列表的一种过敏原溶液施用于通过实施例3乳液保护的皮肤外植体(测试)和未保护的皮肤外植体(未保护对照)。使其静置至T4h，这代表暴露在过敏原下4小时，没有洗涤或粗糙的摩擦。
平行地，以相同方法制备通过乳液保护但不与测试物质接触的外植体(对照)。
通过CD1a免疫染色分析测量针对过敏原的保护效力。首先，用抗CD1a单克隆抗体(参考IM1590，克隆O10，Beckman Coulter)在室温下免疫染色Langerhan细胞的石蜡切片1小时。用链霉亲和素/生物素系统(Vector，PK-7200)加强该免疫染色并用VIP(Vector，SK-4600)显色。用马松苏木精明矾复染细胞核。计数每个切片沿着表皮的Langerhan细胞。用Olympus Cell软件测量每个切片的长度，计算每厘米表皮中Langerhan平均细胞数。
通过没有迁移的Langerhan细胞数测量针对免疫原的保护效力。
在T0和T4h对所有外植体取样并显微拍照。
结果如图1和2所示。图1表示T0时针对橡胶蛋白的外植体，图2表示T4h时针对橡胶蛋白的外植体。
在T0，角质层薄，紧凑且在表面适度填充有角蛋白，在底部更为明显。表皮显示出4-5层细胞，形态良好，生发层有轻微海绵状结构。真皮和表皮之间交界处轮廓明显。乳头状真皮显示出构成致密网络的相当厚的纤维，且它被细胞很好地填充，且不包含明显的组织裂解区。
未保护外植体的表皮显示出4-5层细胞，具有明显的形态改变。这些改变的特征是明显胞浆变性(蛋白质变化)、明显的萎缩和生发层中明显的海绵状结构。
另一方面，经保护的和“对照”外植体没有明显的组织学改变。
测试的每个其他过敏原中获得相似的结果。
不存在细胞改变或低水平的细胞改变以及低浓度的白细胞介素表明，实施例3组合物有效地保护了皮肤免受橡胶蛋白的伤害。
实施例5：避孕套组合物
用以下方法制备包含以下组分的100ml润滑凝胶：
99ml纯水，
0.5g硬葡聚糖，
0.4mg两性螯合剂。
通过以剂量2.0+/-0.5mg/cm2在由天然橡胶制成的避孕套内部和外部表面涂覆来应用所述凝胶。
Claims (12)
1.至少一种两性螯合剂用于预防接触性过敏，尤其是对橡胶过敏的用途，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，和c’是具有与c相同的绝对值的相对数。
2.根据权利要求1所述的用途，其特征在于所述接触性过敏是对致敏物质的过敏、接触性皮炎、接触性荨麻疹、湿疹、鼻炎、结膜炎、哮喘、或过敏性休克。
3.根据权利要求1或2所述的用途，其中所述螯合剂与皮肤和/或黏膜接触。
4.根据权利要求1-3任一项所述的用途，其中将所述两性化合物加入设备和/或组合物中。
5.包含由含有致敏剂材料制成的部分的设备，所述设备意欲用于接触皮肤或黏膜，所述部分用包含至少一种两性螯合剂的层覆盖，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，和c’是具有与c相同的绝对值的相对数。
6.根据权利要求5所述的设备，选自避孕套、手套、指套、绷带和止血敷料、医疗设备例如导管、管、排水设备、灌注装置、用于泌尿科的医疗设备、和用于呼吸通道的医疗设备。
7.根据权利要求5或6所述的设备，其中所述两性螯合剂存在于至少沉积在意欲与皮肤和/或黏膜接触的表面上的膜中。
8.包含至少一种两性螯合剂和至少一种赋形剂的组合物用于预防接触性过敏，尤其是对橡胶过敏的用途，所述两性螯合剂包含基于铝和乙二胺四乙酸或其三钠盐的络合物，其通式为[Al(Y)Bn]c’Dc，其中B是OH-、BO2 -或H+，Y是可以质子化四次从而形成乙二胺四乙酸的四羧酸酯，n是等于0、1、2或3的整数，D是抗衡离子，优选Na+，c是等于0、1、2或3的整数，和c’是具有与c相同的绝对值的相对数。
9.根据权利要求8所述的用途，其特征在于所述赋形剂选自胶凝剂、表面活性剂、合成或天然的蜡或油、保湿剂和润肤剂、止汗剂、质地改进添加剂如调节剂和增稠剂、防腐剂、化妆品和食品染料、香料、调料、pH调节剂、和它们的混合物。
10.根据权利要求9所述的用途，其特征在于所述胶凝剂选自亲水性胶凝剂，例如丙烯酸聚合物和共聚物、C10-C30烷基丙烯酸酯/丙烯酸酯交联聚合物、聚丙烯酰胺、泊洛沙姆、纤维素基衍生物(酯和醚)、二氧化硅、硅酸盐、例如镁-铝硅酸盐、甲壳素及其衍生物、明胶、黄原胶、葡聚糖、结冷胶、角叉菜胶、藻酸盐、琼脂、琼脂、果胶、金合欢树胶、刺梧桐胶、黄蓍胶、阿拉伯胶、瓜尔豆胶、角豆胶、淀粉及其衍生物、或硬葡聚糖；和硅氧烷型胶凝剂，例如聚硅氧烷。
11.根据权利要求7-9任一项所述的用途，其特征在于所述组合物是选自亲水性润滑制剂、硅氧烷润滑制剂或凡士林基润滑制剂的润滑制剂。
12.根据权利要求1-11任一项所述的用途或设备，其特征在于所述两性螯合剂用选自甘氨酸、组氨酸、精氨酸、赖氨酸、苯丙氨酸、丙氨酸、异亮氨酸、亮氨酸、蛋氨酸、脯氨酸，缬氨酸、色氨酸、丝氨酸、谷氨酰胺、胱氨酸和它们的混合物的氨基酸稳定。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810186400.4A CN108606964A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1256939 | 2012-07-18 | ||
| FR1256939A FR2993466B1 (fr) | 2012-07-18 | 2012-07-18 | Utilisation d'une creme de protection contre les effets des agents chimiques agressifs en contact avec la peau |
| PCT/FR2013/051718 WO2014013195A1 (fr) | 2012-07-18 | 2013-07-17 | Utilisation d'un agent chelatant amphotere pour prevenir les allergies de contact |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810186400.4A Division CN108606964A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104470501A true CN104470501A (zh) | 2015-03-25 |
Family
ID=47137836
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910485746.9A Pending CN110179686A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
| CN201810186400.4A Pending CN108606964A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
| CN201380037758.6A Pending CN104507501A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
| CN201380037698.8A Pending CN104470501A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910485746.9A Pending CN110179686A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
| CN201810186400.4A Pending CN108606964A (zh) | 2012-07-18 | 2013-07-17 | 两性螯合剂用于预防接触性过敏的用途 |
| CN201380037758.6A Pending CN104507501A (zh) | 2012-07-18 | 2013-07-17 | 防护与皮肤接触的化学侵蚀剂作用的霜的用途 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US11197874B2 (zh) |
| EP (2) | EP2874604B1 (zh) |
| CN (4) | CN110179686A (zh) |
| AU (2) | AU2013291792B2 (zh) |
| BR (2) | BR112015001019B1 (zh) |
| CA (2) | CA2878882C (zh) |
| DK (2) | DK2874661T3 (zh) |
| ES (2) | ES2690060T3 (zh) |
| FR (1) | FR2993466B1 (zh) |
| IN (1) | IN2014DN10924A (zh) |
| MX (2) | MX359747B (zh) |
| NO (1) | NO2874604T3 (zh) |
| NZ (2) | NZ703409A (zh) |
| PL (2) | PL2874661T3 (zh) |
| PT (1) | PT2874604T (zh) |
| SI (1) | SI2874661T1 (zh) |
| TR (1) | TR201815143T4 (zh) |
| WO (2) | WO2014013195A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3093001B1 (fr) * | 2019-02-22 | 2022-06-10 | Prevor Int | Composition pour enlever des residus chimiques et ses utilisations |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1296667B1 (fr) * | 2000-06-07 | 2006-03-01 | Marie-Claude Meyer | Composes pour la prevention et/ou le traitement des urticaires |
| CN1867547A (zh) * | 2003-10-14 | 2006-11-22 | 奥克萨根有限公司 | 具有crth2拮抗活性的化合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2604900B1 (fr) | 1986-10-08 | 1989-01-13 | Blomet Marie Claude | Solution physiologique pour le lavage des parties du corps humain ayant ete mises en contact avec un acide fluorhydrique et concentre pour sa preparation |
| US5091171B2 (en) * | 1986-12-23 | 1997-07-15 | Tristrata Inc | Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use |
| US5587400A (en) * | 1993-04-19 | 1996-12-24 | Marie-Claude Blomet epouse Meyer | Physiological composition for the treatment of thermal or chemical burns |
| US5665804A (en) * | 1996-02-05 | 1997-09-09 | Dow Corning Corporation | Silicone latex solvent thickening |
| SE9604610D0 (sv) * | 1996-12-16 | 1996-12-16 | Noviscens Ab | Medical composition |
| US6242042B1 (en) * | 1998-09-14 | 2001-06-05 | Lrc Products Ltd. | Aqueous coating composition and method |
| US6582683B2 (en) * | 2000-01-04 | 2003-06-24 | Skinvisible Pharmaceuticals, Inc. | Dermal barrier composition |
| GB0403702D0 (en) * | 2004-02-19 | 2004-03-24 | Boots Co Plc | Skincare compositions |
| JP2007508363A (ja) * | 2003-10-14 | 2007-04-05 | オキサジェン リミテッド | Ｃｒｔｈ２アンタゴニスト活性を有する化合物 |
| US20090019224A1 (en) * | 2005-02-02 | 2009-01-15 | Pocrass Alan L | Data Storage and Transfer Device and Method |
| MY161558A (en) * | 2008-01-18 | 2017-04-28 | Vystar Corp | Natural rubber latex having reduced allergenicity and method of making |
| EP2482807A4 (en) * | 2009-10-02 | 2013-04-24 | Brigham & Womens Hospital | COMPOSITIONS AND METHODS FOR PROPHYLAXIS FOR CONTACT ECZEMA |
-
2012
- 2012-07-18 FR FR1256939A patent/FR2993466B1/fr active Active
-
2013
- 2013-07-17 NO NO13747452A patent/NO2874604T3/no unknown
- 2013-07-17 WO PCT/FR2013/051718 patent/WO2014013195A1/fr active Application Filing
- 2013-07-17 EP EP13747452.4A patent/EP2874604B1/fr active Active
- 2013-07-17 MX MX2015000785A patent/MX359747B/es active IP Right Grant
- 2013-07-17 CN CN201910485746.9A patent/CN110179686A/zh active Pending
- 2013-07-17 BR BR112015001019-9A patent/BR112015001019B1/pt active IP Right Grant
- 2013-07-17 ES ES13747451.6T patent/ES2690060T3/es active Active
- 2013-07-17 AU AU2013291792A patent/AU2013291792B2/en active Active
- 2013-07-17 AU AU2013291793A patent/AU2013291793B2/en active Active
- 2013-07-17 EP EP13747451.6A patent/EP2874661B1/fr active Active
- 2013-07-17 PT PT137474524T patent/PT2874604T/pt unknown
- 2013-07-17 DK DK13747451.6T patent/DK2874661T3/en active
- 2013-07-17 US US14/415,146 patent/US11197874B2/en active Active
- 2013-07-17 BR BR112015001018-0A patent/BR112015001018B1/pt active IP Right Grant
- 2013-07-17 IN IN10924DEN2014 patent/IN2014DN10924A/en unknown
- 2013-07-17 DK DK13747452.4T patent/DK2874604T3/en active
- 2013-07-17 CN CN201810186400.4A patent/CN108606964A/zh active Pending
- 2013-07-17 NZ NZ703409A patent/NZ703409A/en unknown
- 2013-07-17 PL PL13747451T patent/PL2874661T3/pl unknown
- 2013-07-17 CN CN201380037758.6A patent/CN104507501A/zh active Pending
- 2013-07-17 US US14/415,428 patent/US10953024B2/en active Active
- 2013-07-17 CN CN201380037698.8A patent/CN104470501A/zh active Pending
- 2013-07-17 SI SI201331206T patent/SI2874661T1/sl unknown
- 2013-07-17 TR TR2018/15143T patent/TR201815143T4/tr unknown
- 2013-07-17 PL PL13747452T patent/PL2874604T3/pl unknown
- 2013-07-17 CA CA2878882A patent/CA2878882C/fr active Active
- 2013-07-17 WO PCT/FR2013/051717 patent/WO2014013194A1/fr active Application Filing
- 2013-07-17 NZ NZ703258A patent/NZ703258A/en unknown
- 2013-07-17 MX MX2015000786A patent/MX356811B/es active IP Right Grant
- 2013-07-17 ES ES13747452.4T patent/ES2667709T3/es active Active
- 2013-07-17 CA CA2878650A patent/CA2878650C/fr active Active
-
2021
- 2021-02-10 US US17/172,434 patent/US20210275553A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1296667B1 (fr) * | 2000-06-07 | 2006-03-01 | Marie-Claude Meyer | Composes pour la prevention et/ou le traitement des urticaires |
| CN1867547A (zh) * | 2003-10-14 | 2006-11-22 | 奥克萨根有限公司 | 具有crth2拮抗活性的化合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2725907T3 (en) | PROCEDURE FOR TREATING EXEMS | |
| KR20190037229A (ko) | 상승효과적 항진균 조성물 및 그의 방법 | |
| CN109152716B (zh) | 牛磺酸和芦荟协同抗刺激组合物及方法 | |
| WO2007094332A1 (ja) | 消毒用軟膏剤 | |
| KR20070110402A (ko) | 보툴리눔 독소의 국소 적용 및 경피 전달을 위한 조성물 및방법 | |
| US9597276B2 (en) | Composition for the prophylaxis of candidiasis | |
| JP2007284412A (ja) | 殺菌消毒クリーム | |
| EP1593371A1 (en) | Skin or hair care composition | |
| CN104470501A (zh) | 两性螯合剂用于预防接触性过敏的用途 | |
| CA2595615C (en) | Feminine anti-itch gel | |
| CN112107526A (zh) | 一种修复皮肤屏障的婴童护肤品组合物及其制备方法 | |
| EP3226827A1 (en) | Aluminium-free antiperspirant/deodorant compositions and method of preparing the same | |
| JP2007099657A (ja) | 保湿用の液状化粧料 | |
| JP4513518B2 (ja) | パック化粧料 | |
| KR100539761B1 (ko) | 유화제 Free 저자극 여드름 화장료 | |
| TWI504347B (zh) | Anti-mosquito microcapsule composition, anti-mosquito microcapsule, anti-mosquito spray and anti-mosquito emulsion | |
| CN102176892B (zh) | 甜菜碱的应用 | |
| JP2011213671A (ja) | 皮膚外用剤 | |
| JP5483820B2 (ja) | 抗菌性組成物及びデオドラント剤 | |
| BR102017008998A2 (pt) | composição formadora de filme e método de aplicação de composiçao formadora de filme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150325 |